These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29958628)

  • 1. Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?
    Frega S; Bonanno L; Guarneri V; Conte P; Pasello G
    Crit Rev Oncol Hematol; 2018 Aug; 128():19-29. PubMed ID: 29958628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
    Wrona A; Dziadziuszko R; Jassem J
    Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
    Levy A; Faivre-Finn C; Hasan B; De Maio E; Berghoff AS; Girard N; Greillier L; Lantuéjoul S; O'Brien M; Reck M; Dingemans AC; Novello S; Berghmans T; Besse B; Hendriks L;
    Eur J Cancer; 2018 Apr; 93():37-46. PubMed ID: 29477100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?
    Rossi S; Finocchiaro G; Marchetti S; Toschi L; Santoro A
    Immunotherapy; 2018 Apr; 10(5):403-410. PubMed ID: 29473467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
    Liao BC; Lin CC; Yang JC
    Expert Opin Pharmacother; 2018 Jun; 19(8):851-864. PubMed ID: 29726292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
    Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
    Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden.
    Fernandes AW; Wu B; Turner RM
    J Med Econ; 2017 Nov; 20(11):1136-1147. PubMed ID: 28758857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC].
    Lan Q; Ji C; Yao Y
    Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):512-519. PubMed ID: 31451142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
    Soria JC; Mok TS; Cappuzzo F; Jänne PA
    Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
    Brower JV; Robins HI
    Expert Opin Pharmacother; 2016; 17(7):1013-21. PubMed ID: 26967582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.